- Home
- ASRT vs AVTX Comparison
ASRT vs AVTX Comparison
Compare ASRT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- AVTX
- Stock Information
- Founded
- ASRT 1995
- AVTX 2011
- Country
- ASRT United States
- AVTX United States
- Employees
- ASRT N/A
- AVTX N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- AVTX Health Care
- Exchange
- ASRT Nasdaq
- AVTX Nasdaq
- Market Cap
- ASRT 79.1M
- AVTX 248.3M
- IPO Year
- ASRT 1997
- AVTX 2015
- Fundamental
- Price
- ASRT $0.83
- AVTX $17.54
- Analyst Decision
- ASRT Strong Buy
- AVTX Strong Buy
- Analyst Count
- ASRT 1
- AVTX 9
- Target Price
- ASRT $3.00
- AVTX $30.14
- AVG Volume (30 Days)
- ASRT 216.1K
- AVTX 500.3K
- Earning Date
- ASRT 11-10-2025
- AVTX 11-06-2025
- Dividend Yield
- ASRT N/A
- AVTX N/A
- EPS Growth
- ASRT N/A
- AVTX N/A
- EPS
- ASRT N/A
- AVTX N/A
- Revenue
- ASRT $117,099,000.00
- AVTX $441,000.00
- Revenue This Year
- ASRT N/A
- AVTX N/A
- Revenue Next Year
- ASRT $4.10
- AVTX N/A
- P/E Ratio
- ASRT N/A
- AVTX N/A
- Revenue Growth
- ASRT N/A
- AVTX N/A
- 52 Week Low
- ASRT $0.51
- AVTX $3.39
- 52 Week High
- ASRT $1.16
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- ASRT 44.80
- AVTX 76.30
- Support Level
- ASRT $0.80
- AVTX $13.60
- Resistance Level
- ASRT $0.88
- AVTX $15.99
- Average True Range (ATR)
- ASRT 0.04
- AVTX 1.38
- MACD
- ASRT -0.01
- AVTX 0.27
- Stochastic Oscillator
- ASRT 29.40
- AVTX 73.32
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).